EGFR and cancer: Until final OS data and data from studies directly comparing osimertinib with approved 2nd gen TKI (afatinib, dacomitinib), erlotinib/antiangiogenic and gefitinib/chemotherapy combinations become available, selection of the first-line EGFR TKI should be supported by real-world evidence matching the cancer care setting and patient population at the treating center for shared decision making.